Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
TravereTherapeutics: Eric Dube, Ph.D., to Step Down as Pres and CEO in Dec >TVTX ...
Travere Therapeutics stock is little changed today, trading near $62.86 while the company announces a leadership transition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results